GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relay Therapeutics Inc (NAS:RLAY) » Definitions » Total Stockholders Equity

Relay Therapeutics (Relay Therapeutics) Total Stockholders Equity : $745.76 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Relay Therapeutics Total Stockholders Equity?

Relay Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $745.76 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Relay Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $5.64. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Relay Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.07.

Relay Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Relay Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relay Therapeutics Total Stockholders Equity Chart

Relay Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
Get a 7-Day Free Trial -180.44 763.29 897.81 950.22 752.00

Relay Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 883.41 810.12 778.37 752.00 745.76

Relay Therapeutics  (NAS:RLAY) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Relay Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(745.764-0)/132.301
=5.64

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Relay Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(5.147 + 47.159) / 745.764
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relay Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Relay Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Relay Therapeutics (Relay Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relay Therapeutics Inc (NAS:RLAY) » Definitions » Total Stockholders Equity
Comparable Companies
ADMA MDXG ARDX ICPT SAVA OLMA ARVN INVA SRRK COGT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
399 Binney Street, 2nd Floor, Cambridge, MA, USA, 02139
Website
https://www.relaytx.com
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Executives
Peter Rahmer officer: See remarks C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Thomas Catinazzo officer: Vice President, Finance C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Donald A Bergstrom officer: See Remarks 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Brian Adams officer: General Counsel 750 LEXINGTON AVENUE, NEW YORK NY 10022
Sanjiv Patel director, officer: President and CEO C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Andy Porter officer: See Remarks C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Mark Murcko director C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Sekar Kathiresan director 500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Third Rock Ventures Iii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Jami Rubin director C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Douglas S Ingram director 2525 DUPONT DR, IRVINE CA 92612
Third Rock Ventures Gp Iv, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Svf Pauling (cayman) Ltd 10 percent owner 27 HOSPITAL ROAD, GEORGE TOWN, GEORGE TOWN E9 KY1-9008
Picularium, Llc 10 percent owner 1166 AVENUE OF THE AMERICAS, NINTH FLOOR, NEW YORK NY 10036
Laura Shawver director 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518